Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. The management discussed investments planned in their acquired US entity (AGD Nutrition) of approximately $1-2 million over the next year for capacity expansions and partnerships, but this appears to be funded internally. The company is focusing on monetizing real estate assets as a potential source of funds; however, no timelines or commitments on proceeds or equity/debt issuance are given. The company emphasizes strengthening operations and capacity utilization rather than raising ext

Any current/future capex/capital investment/strategic investment?

The company is commissioning a new plant this quarter to increase human Vitamin D3 capacity by around 25% next year. They are investing in backward integration for cholesterol manufacturing from fish oil, expecting EBITDA contribution to start soon with projected Rs.14-15 crore annual EBITDA. Post-acquisition of AGD Nutrition, they anticipate investing an additional 1-2 million USD in the acquired entity over the next year for developing value-added products in human Vitamin D3. Plans to enter the nutrition space beyond Vitamin D3, including Vitamin K1 (plant ready this year) and vitamin AD2 f

Future growth expectations in sales/revenue/volumes?

Human Vitamin D3 business volume growth has been strong, with a 61% increase in volumes reported for nine months FY21, driven primarily by COVID-related demand and new customer additions. Price increase in human Vitamin D3 was modest (~6%), with most growth volume-driven. Animal feed segment experienced a de-growth due to COVID impact on consumption but expected to rebound as normalcy returns. Capacity expansion underway: Human Vitamin D3 capacity to increase by ~25% with a new plant commissioning expected to start contributing next quarter. US market expansion via acquisition of AGD Nutrition

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is increasing human Vitamin D3 capacity by approximately 25% with a new plant commissioning expected by next quarter, which should drive volume growth. Backward integration via the cholesterol manufacturing facility is expected to contribute annual EBITDA of Rs.14-15 crore starting soon, improving margins. The COVID-19 pandemic has positively impacted human D3 demand, with 61% volume growth in nine months FY21; this surge is partly due to new customer additions. The acquisition of AGD Nutrition (now Fermenta USA LLC) aims to grow the US market share with potential investments of $1

Fermenta Biotech LtdQ3 FY21Pharmaceuticals & Biotechnology

Fermenta Biotech Ltd Q3 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹553P/E: 25.2Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Human Vitamin D3 business volume growth has been strong, with a 61% increase in volumes reported for nine months FY21, driven primarily by COVID-related demand and new customer additions.
Price increase in human Vitamin D3 was modest (~6%), with most growth volume-driven.
Animal feed segment experienced a de-growth due to COVID impact on consumption but expected to rebound as normalcy returns.
Capacity expansion underway: Human Vitamin D3 capacity to increase by ~25% with a new plant commissioning expected to start contributing next quarter.
US market expansion via acquisition of AGD Nutrition aims to significantly increase market share, with potential revenue growth through synergy and investments over next 1-2 years.
Nutritional product portfolio expected to expand with new products like Vitamin AD2 formulations and Vitamin K1 planned for launch.
Long-term company outlook sees sustained demand for Vitamin D3 due to its immunity benefits, beyond the COVID spike, though growth rate may normalize.

Margin guidance

Category 3

The company is increasing human Vitamin D3 capacity by approximately 25% with a new plant commissioning expected by next quarter, which should drive volume growth.
Backward integration via the cholesterol manufacturing facility is expected to contribute annual EBITDA of Rs.14-15 crore starting soon, improving margins.
The COVID-19 pandemic has positively impacted human D3 demand, with 61% volume growth in nine months FY21; this surge is partly due to new customer additions.
The acquisition of AGD Nutrition (now Fermenta USA LLC) aims to grow the US market share with potential investments of $1-2 million over the next 1-2 years expected to improve operational capabilities.
Animal feed business has seen a decline due to COVID-19 but is expected to recover as normalcy returns.
Overall, the company expects continued volume-driven growth, margin expansion from backward integration, and market share gains leading to improved future earnings and profitability.

See what Fermenta Biotech Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
The management discussed investments planned in their acquired US entity (AGD Nutrition) of approximately $1-2 million over the next year for capacity expansions and partnerships, but this appears to be funded internally.
The company is focusing on monetizing real estate assets as a potential source of funds; however, no timelines or commitments on proceeds or equity/debt issuance are given.
The company emphasizes strengthening operations and capacity utilization rather than raising external capital at this time.
No mention of issuing new equity or taking on additional debt financing was made during the call or in the provided transcript pages.

Order book

The transcript provided does not explicitly mention the current or expected order book or pending orders for Fermenta Biotech Limited. However, based on relevant insights from the Q3FY21 earnings call: - Human Vitamin D3 business saw a significant 61% volume growth in nine months FY21, indicating strong demand. - Animal feed vitamin D3 segment faced a 55% volume de-growth due to COVID-19 impact on consumption. - Capacity expansion underway with a new plant expected to commission during Q4 FY21 to enhance human vitamin D3 production by ~25%. - Contract manufacturing for animal feed Vitamin D3 has been started in Germany to support future demand. - The acquisition of 52% stake in Fermenta USA LLC aims to boost US market presence and increase order inflow. - Focus on expanding nutritional product basket and premix products suggests expected order growth in these segments. No explicit figures on the order book or pending orders are disclosed in the transcript.

See what Fermenta Biotech Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is commissioning a new plant this quarter to increase human Vitamin D3 capacity by around 25% next year.
They are investing in backward integration for cholesterol manufacturing from fish oil, expecting EBITDA contribution to start soon with projected Rs.14-15 crore annual EBITDA.
Post-acquisition of AGD Nutrition, they anticipate investing an additional 1-2 million USD in the acquired entity over the next year for developing value-added products in human Vitamin D3.
Plans to enter the nutrition space beyond Vitamin D3, including Vitamin K1 (plant ready this year) and vitamin AD2 formulations targeted for launch early next year.
Intends to invest in premix plants to offer mixed vitamin and mineral formulations in the B2B nutrition segment.
No further capital investment planned in real estate; focus is on monetizing existing assets without timeline commitment.

Track Fermenta Biotech Ltd — get its next earnings analysis in your feed

How does Fermenta Biotech Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisFermenta Biotech Ltd

Rev 2Mar 3

See where Fermenta Biotech Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Fermenta Biotech Ltd rank in Pharmaceuticals & Biotechnology?

Compare Fermenta Biotech Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY21) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Fermenta Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →